Date: May 12, 2011

Through: Carol Holquist, RPh, Division Director
Division of Medication Error Prevention and Analysis (DMEPA)

From: Denise V. Baugh, PharmD, BCPS, Safety Evaluator
Division of Medication Error Prevention and Analysis

Subject: Proprietary Name Review

Drug Name and Strengths, Application Types/Numbers:
Xarelto (Rivaroxaban) Tablets
10 mg
NDA 022406 (Division of Hematology Products)

Xarelto (Rivaroxaban) Tablets
15 mg, 20 mg
NDA 202439 (Division of Cardio-Renal Products)

Applicant: Johnson & Johnson Pharmaceutical Research & Development, LLC on behalf of Ortho-McNeil-Janssen-Pharmaceuticals, Inc.

OSE RCM #: 2011-512
2011-437

*** Note: This review contains proprietary and confidential information that should not be released to the public.***

Reference ID: 2946218
EXECUTIVE SUMMARY

This review summarizes DMEPA’s evaluation of the proposed proprietary name, Xarelto for Rivaroxaban Tablets. Our evaluation did not identify concerns that would render the name unacceptable based on the product characteristics and safety profile known at the time of this review. Thus, DMEPA finds the proposed proprietary name, Xarelto, acceptable for this product. DMEPA will notify the Applicant of these findings via letter.

1 BACKGROUND

1.1 INTRODUCTION

This review responds to a request received from Johnson & Johnson Pharmaceutical Research & Development, LLC on behalf of Ortho-McNeil-Janssen-Pharmaceuticals, Inc., submitted February 18, 2011, to evaluate the proposed proprietary name, Xarelto, regarding promotional concerns and potential name confusion with other proprietary or established drug names based on the product characteristics provided by the Applicant.

The Applicant also submitted container labels and carton labeling which will be reviewed under separate cover (OSE Review #2011-438 and #2011-513).

1.2 REGULATORY HISTORY

Rivaroxaban is the established name for the proposed proprietary name, Xarelto, previously found acceptable by DMEPA (OSE Review # 2007-1832 dated April 30, 2009) under IND# 64,892. At that time the dose was 10 mg taken orally once daily and the indication was for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients undergoing hip replacement or knee replacement surgery. No other indication or treatment regimen was proposed at that time.

1.3 PRODUCT INFORMATION

Xarelto is a new molecular entity which will have two different indications and corresponding treatment regimens. Details are described below.

1.3.1 Prophylaxis of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

Xarelto (Rivaroxaban Tablets) is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients undergoing hip replacement or knee replacement surgery. The recommended oral dose is 10 mg taken once daily with or without food. The initial dose should be taken at least 6 to 10 hours after surgery once hemostasis has been established. Xarelto should be used with caution in patients with CrCl 15 mL/minute to less than 30 mL/minute. It is not recommended in patients with CrCl less than 15 mL/minute. The treatment duration is 35 days (hip surgery) to 14 days (knee surgery). Xarelto will be supplied in bottles of 30 and in a carton containing 10 blister cards of 10 tablets each.

1.3.2 Prevention of Stroke and Systemic Embolism

Xarelto (Rivaroxaban Tablets) is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. The recommended oral dose is 20 mg taken once daily with food in patients with CrCl greater than or equal to 50 mL/minute and 15 mg once daily with food in patients with CrCl between 30 mL/minute and less than 50 mL/minute. Xarelto should be used with caution in patients with CrCl 15 mL/minute to less than 30 mL/minute. It is
not recommended in patients with CrCl less than 15 mL/minute. Xarelto 15 mg tablets will be supplied in bottles of 30 and in a carton containing 10 blister cards of 10 tablets each. Xarelto 20 mg tablets will be supplied in bottles of 30 and bottles of 90 as well as in a carton containing 10 blister cards of 10 tablets each.

Table 1. Proposed Treatment Regimens for Xarelto (Rivaroxaban)

<table>
<thead>
<tr>
<th>Dosage</th>
<th>Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 mg</td>
<td>1 tablet twice daily</td>
</tr>
<tr>
<td>20 mg</td>
<td>1 tablet twice daily</td>
</tr>
</tbody>
</table>

2 METHODS AND MATERIALS

Appendix A describes the general methods and materials used by the Division of Medication Error Prevention and Analysis (DMEPA) when conducting a proprietary name risk assessment for all proprietary names. Sections 2.1 and 2.2 identify specific information associated with the methodology for the proposed proprietary name, Xarelto.

2.1 SEARCH CRITERIA

For this review, particular consideration was given to drug names beginning with the letter ‘X’ when searching to identify potentially similar drug names, as 75% of the confused drug names reported by the USP-ISMP Medication Error Reporting Program involve pairs beginning with the same letter.¹,²

To identify drug names that may look similar to ‘Xarelto’, the DMEPA staff also considers the orthographic appearance of the name on lined and unlined orders. Specific attributes taken into consideration include the length of the name (seven letters), upstrokes (three, upper case ‘X’, lower case ‘l’ and ‘t’), down-strokes (none), cross-strokes (two, upper case ‘X’ and lower case ‘t’) and dotted letters (none). Additionally, several letters in Xarelto may be vulnerable to ambiguity when scripted (see Appendix B). As such, the DMEPA staff also considers these alternate appearances when identifying drug names that may look similar to Xarelto.

When searching to identify potential names that may sound similar to Xarelto, the DMEPA staff searches for names with similar number of syllables (three), stresses (XA-rel-to, xa-REL-to, or za-rel-TO), and placement of vowel and consonant sounds. Additionally, the DMEPA staff considers that pronunciation of parts of the name can vary, such as the letter ‘x’ which may be interpreted as ‘z’ and the letters ‘to’ may be interpreted as ‘tow’.

The Applicant’s intended pronunciation (zah-REL-toe) was also taken into consideration, as it was included in the Proprietary Name Review Request. However, names are often mispronounced and/or spoken with regional accents and dialects, so other potential pronunciations of the name are considered.

2.2 FDA Prescription Analysis Studies

In order to evaluate the potential for misinterpretation of the proposed proprietary name in handwriting and verbal communication of the name, the following inpatient medication order, outpatient and verbal prescriptions were communicated during the FDA prescription studies.

Figure 1. Xarelto Prescription Study (conducted on April 26, 2011)

<table>
<thead>
<tr>
<th>HANDWRITTEN PRESCRIPTION and MEDICATION ORDER</th>
<th>VERBAL PRESCRIPTION</th>
</tr>
</thead>
</table>
| Inpatient Prescription:  
Xarelto 10 mg po daily | “Xarelto 10 mg orally daily” |

Outpatient Prescription:

Xarelto 15 mg  
+ 10 QD daily  
+#80
3 RESULTS

The following sections describe DMEPA’s findings from the database searches, CDER Expert Panel Discussion, and FDA prescription analysis studies.

3.1 DATABASE AND INFORMATION SOURCES

The DMEPA safety evaluator searches yielded a total of 20 names as having some similarity to the proposed proprietary name Xarelto.

Sixteen of the 20 names (Kalbitor, Kaletra, Kariva, Parafon Forte DSC, Ramelteon, Varicella, Verdeso, Vivella Dot, Voltaren, Xalatan, Xalkori***, Xeroflo, Xiaflex***, Xodol, Zarelix, and Zometa) were thought to look like Xarelto. One name (Zarontin) was thought to sound like Xarelto and three names Lorelco, Xarelto, and Xeloda were thought to look and sound like Xarelto.

A search of the United States Adopted Name stem list on April 26, 2011, did not identify any United States Adopted Names (USAN) stem within the proposed name, Xarelto.

3.2 CDER EXPERT PANEL DISCUSSION

The Expert Panel reviewed the pool of names identified by DMEPA safety evaluators (See Section 3.1 above) and did not identify additional names which were thought to have phonetic or orthographic similarity to Xarelto.

DDMAC had no concerns regarding the proposed name from a promotional perspective, and did not offer any additional comments relating to the proposed proprietary name.

3.3 FDA PRESCRIPTION ANALYSIS STUDIES

A total of 41 practitioners responded and none of the names overlapped with existing names. Twenty-five (n = 25) of the participants interpreted the name correctly as ‘Xarelto’ with correct interpretation occurring in the inpatient (n = 10), outpatient (n = 13), and verbal studies (n = 2). The remainder of the responses misinterpreted the drug name. Common misinterpretations included mistaking the first letter ‘X’ for the letter ‘C’, ‘S’ or ‘Z’ and the lower case ‘a’ for ‘e’, ‘y’, ‘o’ or ‘u’. See Appendix C for the complete listing of interpretations from the verbal and written prescription studies.

3.4 COMMENTS FROM THE DIVISION OF HEMATOLOGY PRODUCTS (DHP)

3.4.1 Initial Phase of Review

In response to the OSE March 3, 2011, e-mail, the Division of Hematology Products stated that they concur with DDMAC.

3.4.2 Midpoint of Review

On May 9, 2011, DMEPA notified DHP via e-mail that we find the name, Xarelto, acceptable. Per e-mail correspondence from DHP on May 12, 2011, they “had no objections” to Xarelto.

*** This is proprietary and confidential information that should not be released to the public.***
3.5 COMMENTS FROM THE DIVISION OF CARDIOVASCULAR AND RENAL PRODUCTS

3.5.1 Initial Phase of Review

In response to the OSE March 3, 2011, e-mail, the Division of Cardiovascular and Renal Products (DCRP) stated that they had no objections to the proposed name, Xarelto.

3.5.2 Midpoint of Review

On May 9, 2011, DMEPA notified DCRP via e-mail that we find the name, Xarelto, acceptable. Per e-mail correspondence from DCRP on May 9, 2011, they “have no objections to Xarelto”.

3.6 SAFETY EVALUATOR RISK ASSESSMENT

The primary safety evaluator performed an independent search for names that would represent a potential source of drug name confusion. Additionally, although there were five names (Kaletra, Kariva, Xeroflo, Lorelco, and Zarontin) identified in our databases as well as in our previous review (OSE# 2009-637 dated April 30, 2009), we re-evaluated all the names for their potential for confusion as a result of the change in product characteristics for Xarelto. Furthermore, we considered the vulnerability to confusion that this name would pose if it were available as a single strength product (10 mg).

We identified four additional names (Zaditor, Xiral Zimulti***, ...) thought to look similar to Xarelto and represent a potential source of drug name confusion.

As such, a total of 32 names were further analyzed to determine if the drug names could be confused with Xarelto and if the drug name confusion would likely result in a medication error in the usual practice setting. Thirteen names were identified in our previous review, fifteen new names were identified in our database search, and four were identified in our independent search.

4 DISCUSSION

The proposed name, Xarelto, was evaluated from a safety and promotional perspective based on the product characteristics provided by the Applicant. Furthermore, we sought input from pertinent disciplines involved with the review of this application and considered it accordingly.

4.1 PROMOTIONAL ASSESSMENT

DDMAC had no concerns regarding the proposed name from a promotional perspective, and did not offer any additional comments relating to the proposed name. The Division of Hematology Products, the Division of Cardiovascular Renal Products, and DMEPA concurred with the promotional assessment.

4.2 SAFETY ASSESSMENT

DMEPA identified 19 new names for their potential similarity to the proposed name, Xeralto. No other aspect of the name was identified as a potential source of confusion. Upon evaluation of the similar names, four of the 19 were eliminated from further consideration for the following reasons: two names lacked sufficient orthographic and/or phonetic similarity (Appendix D), one name was identified in our database search and found to be the subject of this review (Appendix E), and one name is a foreign name (Appendix F).

Failure mode and effects analysis (FMEA) was then applied to determine if the proposed proprietary name could potentially be confused with the remaining fifteen names and lead to medication errors. This analysis determined that the name similarity between Xeralto and the
identified names was unlikely to result in medication errors with all of the products identified for the reasons presented in Appendix G.

5 CONCLUSIONS AND RECOMMENDATIONS

The Proprietary Name Risk Assessment findings indicate that the proposed name, Xeralto, is not vulnerable to name confusion that could lead to medication errors, nor is it considered promotional. Thus, the Division of Medication Error Prevention and Analysis (DMEPA) has no objection to the proposed proprietary name, Xeralto, for this product at this time. DMEPA will notify the Applicant of this determination via letter.

If any of the proposed product characteristics as stated in this review are altered, DMEPA rescinds this finding and the name must be resubmitted for review. The conclusions upon re-review are subject to change.

If you have further questions or need clarifications, please contact Sue Kang, OSE Project Manager for the Division of Hematology Products, at 301-796-4216 or Nina Ton, OSE Project Manager for the Division of Cardiovascular and Renal Products, at 301-796-1648.
6 PRIOR OSE REVIEW
OSE Review# 2009-637. DMEPA Proprietary Name Review for Xarelto (Rivaroxaban) Tablets 10 mg, Tselaine Jones Smith; April 30, 2009.

7 REFERENCES

1. Micromedex Integrated Index (http://csi.micromedex.com)
   Micromedex contains a variety of databases covering pharmacology, therapeutics, toxicology and diagnostics.

2. Phonetic and Orthographic Computer Analysis (POCA)
   POCA is a database which was created for the Division of Medication Error Prevention and Analysis, FDA. As part of the name similarity assessment, proposed names are evaluated via a phonetic/orthographic algorithm. The proposed proprietary name is converted into its phonemic representation before it runs through the phonetic algorithm. Likewise, an orthographic algorithm exists which operates in a similar fashion.

3. Drug Facts and Comparisons, online version, St. Louis, MO (http://factsandcomparisons.com)
   Drug Facts and Comparisons is a compendium organized by therapeutic course; it contains monographs on prescription and OTC drugs, with charts comparing similar products.

4. FDA Document Archiving, Reporting & Regulatory Tracking System [DARRTS]
   DARRTS is a government database used to organize Applicant and Applicant submissions as well as to store and organize assignments, reviews, and communications from the review divisions.

5. Division of Medication Errors Prevention and Analysis proprietary name consultation requests
   This is a list of proposed and pending names that is generated by the Division of Medication Error Prevention and Analysis from the Access database/tracking system.

6. Drugs@FDA (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm)
   Drugs@FDA contains most of the drug products approved since 1939. The majority of labels, approval letters, reviews, and other information are available for drug products approved from 1998 to the present. Drugs@FDA contains official information about FDA approved brand name, generic drugs, therapeutic biological products, prescription and over-the-counter human drugs and discontinued drugs and “Chemical Type 6” approvals.

7. Electronic online version of the FDA Orange Book (http://www.fda.gov/cder/ob/default.htm)
   The FDA Orange Book provides a compilation of approved drug products with therapeutic equivalence evaluations.

USPTO provides information regarding patent and trademarks.

9. **Clinical Pharmacology Online** ([www.clinicalpharmacology-ip.com](http://www.clinicalpharmacology-ip.com))

Clinical Pharmacology contains full monographs for the most common drugs in clinical use, plus mini monographs covering investigational, less common, combination, nutraceutical and nutritional products. It also provides a keyword search engine.

10. **Data provided by Thomson & Thomson’s SAEGIS™ Online Service, available at** ([www.thomson-thomson.com](http://www.thomson-thomson.com))

The Pharma In-Use Search database contains over 400,000 unique pharmaceutical trademarks and trade names that are used in about 50 countries worldwide. The data is provided under license by IMS HEALTH.

11. **Natural Medicines Comprehensive Databases** ([www.naturaldatabase.com](http://www.naturaldatabase.com))

Natural Medicines contains up-to-date clinical data on the natural medicines, herbal medicines, and dietary supplements used in the western world.

12. **Stat!Ref** ([www.statref.com](http://www.statref.com))

Stat!Ref contains full-text information from approximately 30 texts; it includes tables and references. Among the database titles are: Handbook of Adverse Drug Interactions, Rudolphs Pediatrics, Basic Clinical Pharmacology, and Dictionary of Medical Acronyms Abbreviations.


USAN Stems List contains all the recognized USAN stems.

14. **Red Book Pharmacy’s Fundamental Reference**

Red Book contains prices and product information for prescription, over-the-counter drugs, medical devices, and accessories.

15. **Lexi-Comp** ([www.lexi.com](http://www.lexi.com))

Lexi-Comp is a web-based searchable version of the Drug Information Handbook.

16. **Medical Abbreviations Book**

Medical Abbreviations Book contains commonly used medical abbreviations and their definitions
APPENDICES

Appendix A:

FDA’s Proprietary Name Risk Assessment considers the potential for confusion between the proposed proprietary name and the proprietary and established names of drug products existing in the marketplace and those pending IND, NDA, BLA, and ANDA products currently under review by the Center. DMEPA defines a medication error as any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. 3

For the proposed proprietary name, DMEPA staff search a standard set of databases and information sources to identify names with orthographic and phonetic similarity and hold a Center for Drug Evaluation and Research (CDER) Expert Panel discussion to gather professional opinions on the safety of the proposed proprietary name. DMEPA staff also conducts internal CDER prescription analysis studies. When provided, DMEPA considers external prescription analysis study results and incorporate into the overall risk assessment.

The Safety Evaluator assigned to the Proprietary Name Risk Assessment is responsible for considering the collective findings, and provides an overall risk assessment of the proposed proprietary name. DMEPA bases the overall risk assessment on the findings of a Failure Mode and Effects Analysis (FMEA) of the proprietary name, and focuses on the avoidance of medication errors.

FMEA is a systematic tool for evaluating a process and identifying where and how it might fail. 4 DMEPA uses FMEA to analyze whether the drug names identified with orthographic or phonetic similarity to the proposed proprietary name could cause confusion that subsequently leads to medication errors in the clinical setting. DMEPA uses the clinical expertise of its staff to anticipate the conditions of the clinical setting where the product is likely to be used based on the characteristics of the proposed product.

In addition, the product characteristics provide the context for the verbal and written communication of the drug names and can interact with the orthographic and phonetic attributes of the names to increase the risk of confusion when there is overlap or, in some instances, decrease the risk of confusion by helping to differentiate the products through dissimilarity. Accordingly, the DMEPA staff considers the product characteristics associated with the proposed drug throughout the risk assessment because the product characteristics of the proposed may provide a context for communication of the drug name and ultimately determine the use of the product in the usual clinical practice setting.

Typical product characteristics considered when identifying drug names that could potentially be confused with the proposed proprietary name include, but are not limited to; established name of the proposed product, proposed indication of use, dosage form, route of administration, strength, unit of measure, dosage units, recommended dose, typical quantity or volume, frequency of administration, product packaging, storage conditions, patient population, and prescriber population. Because drug name confusion can occur at any point in the medication use process,


DMEPA staff considers the potential for confusion throughout the entire U.S. medication use process, including drug procurement, prescribing and ordering, dispensing, administration, and monitoring the impact of the medication. DMEPA provides the product characteristics considered for this review in section one.

The Division of Medication Error Prevention and Analysis considers the spelling of the name, pronunciation of the name when spoken, and appearance of the name when scripted. DMEPA also compares the spelling of the proposed proprietary name with the proprietary and established name of existing and proposed drug products because similarly in spelled names may have greater likelihood to sound similar to one another when spoken or look similar to one another when scripted. DMEPA staff also examines the orthographic appearance of the proposed name using a number of different handwriting samples. Handwritten communication of drug names has a long-standing association with drug name confusion. Handwriting can cause similarly and even dissimilarly spelled drug name pairs to appear very similar to one another. The similar appearance of drug names when scripted has led to medication errors. The DMEPA staff applies expertise gained from root-cause analysis of such medication errors to identify sources of ambiguity within the name that could be introduced when scripting (e.g., “T” may look like “F,” lower case ‘a’ looks like a lower case ‘u,’ etc). Additionally, other orthographic attributes that determine the overall appearance of the drug name when scripted (see Table 1 below for details). In addition, the DMEPA staff compares the pronunciation of the proposed proprietary name with the pronunciation of other drug names because verbal communication of medication names is common in clinical settings. If provided, DMEPA will consider the Applicant’s intended pronunciation of the proprietary name. However, DMEPA also considers a variety of pronunciations that could occur in the English language because the Applicant has little control over how the name will be spoken in clinical practice.

Table 1. Criteria used to identify drug names that look- or sound-similar to a proposed proprietary name.

<table>
<thead>
<tr>
<th>Type of similarity</th>
<th>Considerations when searching the databases</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Potential causes of drug name similarity</strong></td>
</tr>
<tr>
<td>Look-alike</td>
<td>Similar spelling</td>
</tr>
<tr>
<td></td>
<td>Orthographic similarity</td>
</tr>
</tbody>
</table>

Lastly, the DMEPA staff also considers the potential for the proposed proprietary name to inadvertently function as a source of error for reasons other than name confusion. Post-marketing experience has demonstrated that proprietary names (or components of the proprietary name) can be a source of error in a variety of ways. Consequently, DMEPA considers and evaluates these broader safety implications of the name throughout this assessment and the medication error staff provides additional comments related to the safety of the proposed proprietary name or product based on professional experience with medication errors.

1. **Database and Information Sources**

DMEPA staff conducts searches of the internet, several standard published drug product reference texts, and FDA databases to identify existing and proposed drug names that may sound-alike or look-alike to the proposed proprietary name using the criteria outlined in Section 2.1. Section 6 provides a standard description of the databases used in the searches. To complement the process, the DMEPA staff use a computerized method of identifying phonetic and orthographic similarity between medication names. The program, Phonetic and Orthographic Computer Analysis (POCA), uses complex algorithms to select a list of names from a database that have some similarity (phonetic, orthographic, or both) to the trademark being evaluated. Lastly, the DMEPA staff review the USAN stem list to determine if any USAN stems are present within the proprietary name. The individual findings of multiple safety evaluators are pooled and presented to the CDER Expert Panel.

2. **CDER Expert Panel Discussion**

DMEPA conducts an Expert Panel Discussion to gather CDER professional opinions on the safety of the proposed product and the proposed proprietary name. The Expert Panel is composed of Division of Medication Errors Prevention (DMEPA) staff and representatives from the Division of Drug Marketing, Advertising, and Communications (DDMAC). The Expert Panel also discusses potential concerns regarding drug marketing and promotion related to the proposed names.

The primary Safety Evaluator presents the pooled results of the DMEPA staff to the Expert Panel for consideration. Based on the clinical and professional experiences of the Expert Panel members, the Panel may recommend the addition of names, additional searches by the primary Safety Evaluator to supplement the pooled results, or general advice to consider when reviewing the proposed proprietary name.

3. **FDA Prescription Analysis Studies**

Three separate studies are conducted within the Centers of the FDA for the proposed proprietary name to determine the degree of confusion of the proposed proprietary name with
marketed U.S. drug names (proprietary and established) due to similarity in visual appearance with handwritten prescriptions or verbal pronunciation of the drug name. The studies employ healthcare professionals (pharmacists, physicians, and nurses), and attempts to simulate the prescription ordering process. The primary Safety Evaluator uses the results to identify orthographic or phonetic vulnerability of the proposed name to be misinterpreted by healthcare practitioners.

In order to evaluate the potential for misinterpretation of the proposed proprietary name in handwriting and verbal communication of the name, inpatient medication orders and/or outpatient prescriptions are written, each consisting of a combination of marketed and unapproved drug products, including the proposed name. These orders are optically scanned and one prescription is delivered to a random sample of the 123 participating health professionals via e-mail. In addition, a verbal prescription is recorded on voice mail. The voice mail messages are then sent to a random sample of the participating health professionals for their interpretations and review. After receiving either the written or verbal prescription orders, the participants send their interpretations of the orders via e-mail to DMEPA.

4. Safety Evaluator Risk Assessment of the Proposed Proprietary Name

The primary Safety Evaluator applies his/her individual expertise gained from evaluating medication errors reported to FDA, conducts a Failure Mode and Effects Analysis, and provides an overall risk assessment of name confusion. Failure Mode and Effects Analysis (FMEA) is a systematic tool for evaluating a process and identifying where and how it might fail. When applying FMEA to assess the risk of a proposed proprietary name, DMEPA seeks to evaluate the potential for a proposed proprietary name to be confused with another drug name because of name confusion and, thereby, cause errors to occur in the medication use system. FMEA capitalizes on the predictable and preventable nature of medication errors associated with drug name confusion. FMEA allows the Agency to identify the potential for medication errors due to orthographically or phonetically similar drug names prior to approval, where actions to overcome these issues are easier and more effective than remedies available in the post-approval phase.

In order to perform an FMEA of the proposed name, the primary Safety Evaluator must analyze the use of the product at all points in the medication use system. Because the proposed product is not marketed, the primary Safety Evaluator anticipates the use of the product in the usual practice settings by considering the clinical and product characteristics listed in Section one. The Safety Evaluator then analyzes the proposed proprietary name in the context of the usual practice setting and works to identify potential failure modes and the effects associated with the failure modes.

In the initial stage of the Risk Assessment, the Safety Evaluator compares the proposed proprietary name to all of the names gathered from the above searches, Expert Panel Discussion, and prescription studies, external studies, and identifies potential failure modes by asking:

"Is the proposed proprietary name convincingly similar to another drug name, which may cause practitioners to become confused at any point in the usual practice setting?"

An affirmative answer indicates a failure mode and represents a potential for the proposed proprietary name to be confused with another proprietary or established drug name because of look- or sound-alike similarity. If the answer to the question is no, the Safety Evaluator is not

convinced that the names posses similarity that would cause confusion at any point in the medication use system, thus the name is eliminated from further review.

In the second stage of the Risk Assessment, the primary Safety Evaluator evaluates all potential failure modes to determine the likely effect of the drug name confusion, by asking:

“Could the confusion of the drug names conceivably result in medication errors in the usual practice setting?”

The answer to this question is a central component of the Safety Evaluator’s overall risk assessment of the proprietary name. If the Safety Evaluator determines through FMEA that the name similarity would not ultimately be a source of medication errors in the usual practice setting, the primary Safety Evaluator eliminates the name from further analysis. However, if the Safety Evaluator determines through FMEA that the name similarity could ultimately cause medication errors in the usual practice setting, the Safety Evaluator will then recommend the use of an alternate proprietary name.

DMEPA will object to the use of proposed proprietary name when the primary Safety Evaluator identifies one or more of the following conditions in the Risk Assessment:

a. DDMAC finds the proposed proprietary name misleading from a promotional perspective, and the Review Division concurs with DDMAC’s findings. The Federal Food, Drug, and Cosmetic Act provides that labeling or advertising can misbrand a product if misleading representations are made or suggested by statement, word, design, device, or any combination thereof, whether through a PROPRIETARY name or otherwise [21 U.S.C 321(n); See also 21 U.S.C. 352(a) & (n)].

b. DMEPA identifies that the proposed proprietary name is misleading because of similarity in spelling or pronunciation to another proprietary or established name of a different drug or ingredient [CFR 201.10.(C)(5)].

c. FMEA identifies the potential for confusion between the proposed proprietary name and other proprietary or established drug name(s), and demonstrates that medication errors are likely to result from the drug name confusion under the conditions of usual clinical practice.

d. The proposed proprietary name contains an USAN (United States Adopted Names) stem.

e. DMEPA identifies a potential source of medication error within the proposed proprietary name. For example, the proprietary name may be misleading or, inadvertently, introduce ambiguity and confusion that leads to errors. Such errors may not necessarily involve confusion between the proposed drug and another drug product.

If DMEPA objects to a proposed proprietary name on the basis that drug name confusion could lead to medication errors, the primary Safety Evaluator uses the FMEA process to identify strategies to reduce the risk of medication errors. DMEPA is likely to recommend that the Applicant select an alternative proprietary name and submit the alternate name to the Agency for DMEPA to review. However, in rare instances FMEA may identify plausible strategies that could reduce the risk of medication error of the currently proposed name. In that instance, DMEPA may be able to provide the Applicant with recommendations that reduce or eliminate the potential for error and, thereby, would render the proposed name acceptable.

In the event that DMEPA objects to the use of the proposed proprietary name, based upon the potential for confusion with another proposed (but not yet approved) proprietary name, DMEPA will provide a contingency objection based on the date of approval. Whichever product, the Agency approves first has the right to use the proprietary name, while DMEPA will recommend that the second product to reach approval seek an alternative name.
The threshold set for objection to the proposed proprietary name may seem low to the Applicant. However, the safety concerns set forth in criteria a through e are supported either by FDA regulation or by external healthcare authorities, including the Institute of Medicine (IOM), World Health Organization (WHO), Joint Commission on Accreditation of Hospitals (JCOAH), and the Institute for Safe Medication Practices (ISMP). These organizations have examined medication errors resulting from look- or sound-alike drug names and called for regulatory authorities to address the issue prior to approval. Additionally, DMEPA contends that the threshold set for the Proprietary Name Risk Assessment is reasonable because proprietary drug name confusion is a predictable and a preventable source of medication error that, in many instances, the Agency and/or Applicant can identify and rectify prior to approval to avoid patient harm.

Furthermore, post-marketing experience has demonstrated that medication errors resulting from drug name confusion are notoriously difficult to rectify post-approval. Educational and other post-approval efforts are low-leverage strategies that have had limited effectiveness at alleviating medication errors involving drug name confusion. Applicants have undertaken higher-leverage strategies, such as drug name changes, in the past but at great financial cost to the Applicant and at the expense of the public welfare, not to mention the Agency’s credibility as the authority responsible for approving the error-prone proprietary name. Moreover, even after Applicants’ have changed a product’s proprietary name in the post-approval phase, it is difficult to eradicate the original proprietary name from practitioners’ vocabulary, and as a result, the Agency has continued to receive reports of drug name confusion long after a name change in some instances. Therefore, DMEPA believes that post-approval efforts at reducing name confusion errors should be reserved for those cases in which the potential for name confusion could not be predicted prior to approval. (See Section 4 for limitations of the process).
### Appendix B: Letters with possible orthographic or phonetic misinterpretation

<table>
<thead>
<tr>
<th>Letters in proposed name, Xarelto</th>
<th>Scripted may appear as</th>
<th>Spoken may be interpreted as</th>
</tr>
</thead>
<tbody>
<tr>
<td>lower case ‘a’</td>
<td>e, i, l, p</td>
<td>Any vowel</td>
</tr>
<tr>
<td>lower case ‘r’</td>
<td>s, n, e, v</td>
<td></td>
</tr>
<tr>
<td>lower case ‘e’</td>
<td>a, i, l, p</td>
<td>Any vowel</td>
</tr>
<tr>
<td>lower case ‘t’</td>
<td>b, e, s, i</td>
<td>d</td>
</tr>
<tr>
<td>Lower case ‘o’</td>
<td>a, c, e, u</td>
<td>oh</td>
</tr>
</tbody>
</table>

### Appendix C: FDA Prescription Study Responses for Saflutan (conducted April 26, 2011)

<table>
<thead>
<tr>
<th>Inpatient Medication Order</th>
<th>Outpatient Prescription</th>
<th>Voice Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xarelto</td>
<td>Xarelto</td>
<td>Xorelto</td>
</tr>
<tr>
<td>Xarllo</td>
<td>Xarelto</td>
<td>Xarelto</td>
</tr>
<tr>
<td>Tareeto</td>
<td>xarelto</td>
<td>serelto</td>
</tr>
<tr>
<td>Xarelto</td>
<td>xarelto</td>
<td>Cyrelto</td>
</tr>
<tr>
<td>Xarelto</td>
<td>Xarelto</td>
<td>Zarelto</td>
</tr>
<tr>
<td>Xarelto</td>
<td>Xarelto</td>
<td>Zarelto</td>
</tr>
<tr>
<td>Xarelto</td>
<td>xarelto</td>
<td>Surelto</td>
</tr>
<tr>
<td>Xarelto</td>
<td>xarelto</td>
<td>Ceralto</td>
</tr>
<tr>
<td>Xarelto</td>
<td>Xarelto</td>
<td></td>
</tr>
<tr>
<td>Xarelto</td>
<td>Xarelto</td>
<td></td>
</tr>
<tr>
<td>Xarelto</td>
<td>Xarelto</td>
<td></td>
</tr>
<tr>
<td>Xarelto</td>
<td>Xarelto</td>
<td></td>
</tr>
<tr>
<td>Xarelto</td>
<td>Xarelto</td>
<td></td>
</tr>
<tr>
<td>xareto</td>
<td>xarelto</td>
<td></td>
</tr>
<tr>
<td>xarelto</td>
<td>xarelto</td>
<td></td>
</tr>
<tr>
<td>Xarelto</td>
<td>xarelto</td>
<td></td>
</tr>
</tbody>
</table>
### Appendix D: Proprietary names that lack convincing orthographic and/or phonetic similarities

<table>
<thead>
<tr>
<th>Proprietary Name</th>
<th>Similarity to Xarelto</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xeloda</td>
<td>Look and Sound</td>
</tr>
<tr>
<td>Parafon Forte DSC</td>
<td>Look</td>
</tr>
</tbody>
</table>

### Appendix E: Drug name that is the subject of this review.

<table>
<thead>
<tr>
<th>Proprietary Name</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xarelto (granted approval in Europe September, 2008)</td>
<td>Micromedex, DARRTS, Facts &amp; Comparisons</td>
</tr>
</tbody>
</table>

### Appendix F: Drug name that is foreign and not likely to be confused with ‘Xarelto’.

<table>
<thead>
<tr>
<th>Proprietary Name</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zarelix (Venlafaxine Hydrochloride)</td>
<td>Marketed in Portugal (per Micromedex)</td>
</tr>
</tbody>
</table>
**Appendix G:** Potentially confusing names with orthographic and/or phonetic differences and differentiating product characteristics that decrease the risk of medication errors.

<table>
<thead>
<tr>
<th>Failure Mode: Name confusion</th>
<th>Causes (could be multiple)</th>
<th>Rationale:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Proposed name:</strong> Xarelto (Rivaroxaban) Tablet</td>
<td>Strength: 10 mg, 15 mg, 20 mg</td>
<td>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: 20 mg once daily Prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery: 10 mg once daily</td>
</tr>
<tr>
<td>Kalbitor (Ecallantide) Injection 10 mg/mL</td>
<td>Orthographic similarity stems from similar appearance of first letters (K vs. X) in some handwriting samples. Additionally, both names include two consecutive upstrokes within their names (‘hb’ vs. ‘ht’). Numerical overlap in strength exists (10 mg) as well as the existence of achievable doses (two 10 mg doses = 20 mg and two 15 mg doses = 30 mg).</td>
<td>The marketed name, ‘Kalbitor’, has one additional upper stroke (‘t’) in its name which gives this name a different shape orthographically from the proposed name, ‘Xarelto’. Additionally, the consecutive upstrokes occur earlier in the name, ‘Kalbitor’, versus that of ‘Xarelto’ which occurs near the end of the name. These differences will likely distinguish this name pair from each other. Differing product characteristics include the dose (30 mg vs. 10 mg or 20 mg) and route of administration (subcutaneous vs. oral). Xarelto is available in more than one strength and therefore this information will need to be provided on a prescription to dispense/administer the drug as intended.</td>
</tr>
<tr>
<td><strong>Usual dose:</strong> 30 mg (3 mL) given subcutaneously in three 10 mg (1 mL) injections. Repeat within a 24 hour period if symptoms persist.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ramelteon (active ingredient for the proprietary name, Rozerem) Tablet 8 mg</td>
<td>Orthographic similarity stems from the similar appearance of their first letters (‘R’ vs. ‘X’) in some handwriting samples and the fact that both names share the letters ‘-elt-’ in the same positions within their names. Overlapping product characteristics include route of administration (oral) and frequency of administration (daily).</td>
<td>The marketed name, Ramelteon, terminates with the letters ‘-on’ giving this name a longer appearance and a different shape when compared to the proposed name, Xarelto. This feature may help to distinguish between this name pair. Xarelto is available in more than one strength and therefore this information will need to be provided on a prescription to dispense/administer the drug as intended.</td>
</tr>
<tr>
<td><strong>Usual dose:</strong> One tablet taken within 30 minutes of going to bed.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Failure Mode: Name confusion</td>
<td>Causes (could be multiple)</td>
<td>Rationale:</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Proposed name: Xarelto (Rivaroxaban) Tablet</td>
<td>Strength: 10 mg, 15 mg, 20 mg</td>
<td>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: 20 mg once daily</td>
</tr>
<tr>
<td>Verdeso (Desonide) Foam 0.05%</td>
<td>Orthographic similarity stems from the similar appearance of their first letters (‘V’ vs. ‘X’) in some handwriting samples, the fact that both names have at least one up stroke, and that they both end with an ‘o’.</td>
<td>The marketed name, Verdeso, has one up stroke in the middle of its name whereas the proposed name, Xarelto, has two consecutive up strokes near the end, giving these names different shapes. This difference may distinguish these names from each other. Differing product characteristics include strength (0.05% vs. 10 mg, 20 mg), route of administration (topical vs. oral), and frequency of administration (twice daily vs. once daily). Xarelto is available in more than one strength and therefore this information will need to be provided on a prescription to dispense/administer the drug as intended.</td>
</tr>
<tr>
<td><strong>Usual dose:</strong> Apply a thin layer of foam to the affected area (s) twice daily.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella (the established name for a live vaccine) 1,350 PFU/0.5 mL</td>
<td>Orthographic similarity stems from the similar appearance of their first letters (‘V’ vs. ‘X’) in some handwriting samples, the fact that these names share the same second and third letters (‘ar’) and they both have consecutive up strokes (‘ll’ vs. ‘lt’) within their names.</td>
<td>The marketed name, Varicella, is longer in length than the proposed name, Xarelto. This feature may distinguish this name pair. Differences in product characteristics include dose (0.5 mL vs. 10 mg, 20 mg), route of administration (subcutaneous vs. oral), and frequency of administration (an injection 4 to 8 weeks apart vs. once daily). Xarelto is available in more than one strength and therefore this information will need to be provided on a prescription to dispense/administer the drug as intended.</td>
</tr>
<tr>
<td><strong>Usual dose:</strong> 0.5 mL given subcutaneously at an elected date and a second 0.5 mL dose 4 to 8 weeks later.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Failure Mode: Name confusion</td>
<td>Causes (could be multiple)</td>
<td>Rationale:</td>
</tr>
<tr>
<td>------------------------------</td>
<td>---------------------------</td>
<td>------------</td>
</tr>
</tbody>
</table>
| Proposed name: Xarelto (Rivaroxaban) Tablet | Strength: 10 mg, 15 mg, 20 mg | Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: 20 mg once daily  
Prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery: 10 mg once daily |
| Vivella Dot (Estradiol) Transdermal Patch  
0.025 mg/24 hr, 0.038 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr  
**Usual dose:** Apply twice weekly. | Orthographic similarity stems from the similar appearance of their first letters (‘V’ vs. ‘X’) in some handwriting samples and the fact that they both have consecutive up strokes (‘ll’ vs. ‘lt’) within their names. | The marketed name, Vivella Dot, includes the modifier ‘Dot’ which makes this name longer in appearance than the proposed name, Xarelto. This feature will likely distinguish this name pair from each other.  
Differences in product characteristics include dose (0.025 mg/24 hr, 0.038 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr vs. 10 mg, 20 mg), route of administration (topical vs. oral), and frequency of administration (twice weekly vs. once daily).  
Xarelto and Vivella Dot are both available in more than one strength and therefore this information will need to be provided on a prescription to dispense/administer the drug as intended. |
| Voltaren (Diclofenac) Tablet  
25 mg, 50 mg, 75 mg  
**Usual dose:** 50 mg three times daily | Orthographic similarity stems from similar appearance of their first letters (‘V’ vs. ‘X’) in some handwriting samples and the fact that both names share the letters ‘-lt-’ within their names.  
Overlapping product characteristics include route of administration (oral). | The marketed name, Voltaren, has four letters beyond its consecutive up strokes, ‘-lt-‘. This is in contrast to the proposed name, Xarelto, which has only one letter beyond the letters ‘-lt-‘. This difference gives these names different shapes and may distinguish them from each other.  
One differing product characteristic includes the frequency of administration (three times daily vs. once daily).  
Xarelto and Vivella Dot are both available in more than one strength and therefore this information will need to be provided on a prescription to dispense/administer the drug as intended. |
<table>
<thead>
<tr>
<th>Failure Mode: Name confusion</th>
<th>Causes (could be multiple)</th>
<th>Rationale:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed name: Xarelto (Rivaroxaban) Tablet</td>
<td>Strength: 10 mg, 15 mg, 20 mg</td>
<td>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: 20 mg once daily. Prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery: 10 mg once daily.</td>
</tr>
</tbody>
</table>

**Xalatan (Latanoprost) Ophthalmic Solution 0.005%**

**Usual dose:**
One drop in the affected eye(s) once daily in the evening.

Orthographic similarity stems from sharing the first two letters of their names (‘Xa’) and the fact that both names have the same up strokes (‘l’ and ‘t’).

One overlapping product characteristic is the frequency of administration (once daily).

Although this name pair share the same up strokes, the marketed name, Xalatan, contains solitary up strokes whereas those in the proposed name, Xarelto, are consecutive. The different locations of the letters give the names different shapes and may distinguish them from each other.

Differing product characteristics include strength (0.005% vs. 10 mg, 20 mg) and route of administration (ocular vs. oral).

Xarelto is available in more than one strength and therefore this information will need to be provided on a prescription to dispense/administer the drug as intended.

**Xalkori*** (Crizotinib) Capsules

**Usual dose:**
250 mg orally twice daily (NOTE: DMEPA objected to this name previously [OSE# 2010-1790 dated February 8, 2011]. It is currently being rebutted).

Orthographic similarity stems from sharing the first two letters (‘Xa-’) of their names and the fact that both names have two consecutive up strokes (‘lk’ vs. ‘lt’).

Overlapping product characteristics include route of administration (oral). Numerical overlap in strengths exist (200 mg vs. 20 mg).

The consecutive up strokes in the name, Xalkori*** appear in the third and fourth positions respectively within the name vs. the fifth and sixth position within the proposed name, Xarelto. This difference gives these names different shapes and may distinguish this name pair from each other.

One differing product characteristic is the frequency of administration (twice daily vs. once daily).

Xarelto and Xalkori*** are both available in more than one strength and therefore this information will need to be provided on a prescription to dispense/administer the drug as intended.

*** Note: This review contains proprietary and confidential information that should not be released to the public.***
<table>
<thead>
<tr>
<th>Failure Mode: Name confusion</th>
<th>Causes (could be multiple)</th>
<th>Rationale:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed name: Xarelto (Rivaroxaban) Tablet</td>
<td>Strength: 10 mg, 15 mg, 20 mg</td>
<td>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: 20 mg once daily. Prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery: 10 mg once daily.</td>
</tr>
<tr>
<td>Xodol (Hydrocodone and Acetaminophen) Tablet 10 mg/300 mg, 5 mg/300 mg, 7.5 mg/300 mg</td>
<td>Orthographic similarity stems from the fact that these names share the first letter (‘X’) in their names and both names have up strokes within their names (‘d’ and ‘l’ vs. ‘l’ and ‘t’).</td>
<td>Although both names have up strokes, the marketed name, Xodol, contains solitary up strokes with one appearing at the end of the name whereas those in the proposed name, Xarelto, are consecutive. The different locations of the letters give the names different shapes and may distinguish them from each other. One differing product characteristic is the frequency of administration (every 4 to 6 hours vs. once daily). Xarelto and Xodol are both available in more than one strength and therefore this information will need to be provided on a prescription to dispense/administer the drug as intended.</td>
</tr>
<tr>
<td>Zometa (Zoledronic Acid) Injection 4 mg/5 mL</td>
<td>Orthographic similarity stems from the similar appearance of their first letters (‘Z’ vs ‘X’) in some handwriting samples and the fact that both names share the same cross stroke (‘t’), near the end of its name, whereas the proposed name, Xarelto, contains two consecutive up strokes. This difference may distinguish these names from each other. Differing product characteristics include dose (4 mg vs. 10 mg, 20 mg) and route of administration (intravenous vs. oral). Xarelto is available in more than one strength and therefore this information will need to be provided on a prescription to dispense/administer the drug as intended.</td>
<td>The proposed name, Zometa, contains a solitary cross stroke, ‘t’, near the end of its name, whereas the proposed name, Xarelto, contains two consecutive up strokes. This difference may distinguish these names from each other. Differing product characteristics include dose (4 mg vs. 10 mg, 20 mg) and route of administration (intravenous vs. oral).</td>
</tr>
<tr>
<td>Usual dose:</td>
<td>One tablet every 4 to 6 hours</td>
<td></td>
</tr>
<tr>
<td>Usual dose:</td>
<td>4 mg given intravenously over 15 to 30 minutes as a single dose or given every 3 to 4 weeks depending upon diagnosis</td>
<td></td>
</tr>
<tr>
<td>Failure Mode: Name confusion</td>
<td>Causes (could be multiple)</td>
<td>Rationale:</td>
</tr>
<tr>
<td>------------------------------</td>
<td>---------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Proposed name: Xarelo (Rivaroxaban) Tablet</td>
<td>Strength: 10 mg, 15 mg, 20 mg</td>
<td>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: 20 mg once daily Prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery: 10 mg once daily</td>
</tr>
<tr>
<td>Zaditor (Ketotifen) Ophthalmic Solution 0.025% <strong>Usual dose:</strong> One drop in the affected eye(s) every 8 to 12 hours</td>
<td>Orthographic similarity stems from the similar appearance of their first letters (‘Z’ vs. ‘X’) in some handwriting samples and the fact that they share the letters ‘a’, ‘t’, and ‘o’ in the same or similar positions.</td>
<td>Differing product characteristics include dose (one drop vs. 10 mg, 20 mg), route of administration (ocular vs. oral), and frequency of administration (every 8 to 12 hours vs. once daily). Xarelo is available in more than one strength and therefore this information will need to be provided on a prescription to dispense/administer the drug as intended.</td>
</tr>
<tr>
<td>Xiral (Chlorpheniramine and Methscopolamine and Pseudoephedrine) extended release oral tablet 8 mg/2.5 mg/120 mg <strong>NOTE:</strong> ‘Xiral’ is off the market but components of this combination product are still available <strong>Usual dose:</strong> Varies, not to exceed 240 mg of pseudoephedrine and 24 mg of chlorpheniramine 24 hours</td>
<td>Orthographic similarity stems from sharing the same letters in the same positions within their names (‘X’, ‘r’, and ‘l’). Overlapping product characteristics include route of administration (oral).</td>
<td>The proposed name, Xeralto, has two letters at the end of its name giving it a different shape and longer appearance than the marketed name, Xiral. This difference may distinguish this name pair from each other. Differences in product characteristics include dose (one tablet vs. 10 mg or 20 mg). Xarelo is available in more than one strength and therefore this information will need to be provided on a prescription to dispense/administer the drug as intended.</td>
</tr>
<tr>
<td>Failure Mode: Name confusion</td>
<td>Causes (could be multiple)</td>
<td>Rationale:</td>
</tr>
<tr>
<td>------------------------------</td>
<td>---------------------------</td>
<td>------------</td>
</tr>
</tbody>
</table>
| Proposed name: Xarelto (Rivaroxaban) Tablet | Strength: 10 mg, 15 mg, 20 mg | Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: 20 mg once daily  
Prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery: 10 mg once daily |
| (b)(4) (Norethindrone and Ethinyl Estradiol and Ferrous Fumarate) Tablet 0.8 mg /0.025 mg | Orthographic similarity stems from the similar appearance of their first letters (‘Z’ vs. ‘X’) in some handwriting samples, the fact that both names contain up strokes in the same position within their names, and both names are the same length.  
Overlapping product characteristics include route of administration (oral) and frequency of administration (once daily). | Xarelto is available in more than one strength and therefore this information will need to be provided on a prescription to dispense/administer the drug as intended. |
| Usual dose: One tablet orally once daily  
(Note: DMEPA objected to this name previously [OSE# 2010-929] and the product was approved without a proprietary name [NDA# 22573]) |  | |
| Zimulti*** (Rimonabant) Tablets 20 mg | Orthographic similarity stems from the similar appearance of their first letters (‘Z’ vs. ‘X’) in some handwriting samples, the fact that both names contain the same up strokes in the same position within their names, and both names are the same length.  
Overlapping product characteristics include strength (20 mg), route of administration (oral) and frequency of administration (once daily) | The name Zimulti*** contains the letter ‘m’ which is distinguishable by its double hump appearance. Additionally, the terminal letter for Xarelto is an ‘o’ appears different in this position than the letter ‘i’ which is the last letter in Zimulti***. These differences may help to distinguish this name pair.  
Xarelto is available in three strengths and therefore this information will need to be provided on a prescription to dispense/administer the drug as intended. |
| Usual dose: One tablet every morning before breakfast.  
(NOTE: The Applicant withdrew the unapproved NDA from consideration by the Agency as of June 29, 2007) |  | |

---

*** Note: This review contains proprietary and confidential information that should not be released to the public. ***
<table>
<thead>
<tr>
<th>Failure Mode: Name confusion</th>
<th>Causes (could be multiple)</th>
<th>Rationale:</th>
</tr>
</thead>
</table>
| Proposed name: Xarelto (Rivaroxaban) Tablet | Strength: 10 mg, 15 mg, 20 mg | Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: 20 mg once daily  
Prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery: 10 mg once daily |

Xiaflex (Collagenase Clostridium) Injection  
0.9 mg  
**Usual dose:**  
Inject 0.58 mg into a palpable Dupuytren’s cord according to the injection procedure; may repeat up to three times per cord at 4 week intervals

Orthographic similarity stems from sharing the same first letters ('X') and the fact that both names have consecutive up strokes in their names ('fl' vs. 'lt').

The consecutive up stroke in the name, Xiaflex occurs in the fourth and fifth position whereas they are present in the fifth and sixth position.  
Additionally, the name ‘Xiaflex’ ends with a cross stroke, ('x') which distinguishes this from the last letter ('o') in the proposed name, Xarelto.

Differing product characteristics include dose (0.58 mg vs. 10 mg or 20 mg) and route of administration (injection into palpable Dupuytren’s cord vs. oral), and frequency of administration (once every 3 to 4 weeks if needed vs. once daily).  
Xarelto is available in more than one strength and therefore this information will need to be provided on a prescription to dispense/administer the drug as intended.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DENISE V BAUGH
05/12/2011

CAROL A HOLQUIST
05/12/2011